Community
Our Commitment to the ALS & Neurodegenerative Disease Community
A Patient-Centered Approach
At NeuroSense, patients are at the heart of every decision. The company is dedicated to:
- Transparent communication - keeping the community informed about research and clinical advancements.
- Listening and learning - integrating patient insights into the development process.
- Advocacy and awareness - collaborating with patient organizations to drive meaningful change.
NeuroSense Therapeutics was founded on a mission: to drive innovation for people living with ALS and other neurodegenerative diseases. A pivotal meeting with Shay Rishoni, a visionary leader and ALS advocate, helped lay the foundation for the company. His resilience, determination, and relentless pursuit of a cure continue to inspire and shape NeuroSense’s work, even after his passing.
With this mission in mind, NeuroSense is committed to engaging with the patient community, advocacy organizations, and caregivers to ensure that the needs and experiences of those affected guide the company’s efforts. PrimeC, the company’s lead drug candidate, was named in tribute to Shay Rishoni, honoring his legacy and his vision for a world where ALS is no longer a terminal diagnosis.
“Our commitment to the community is to ensure transparent communication. Insights from patients’ experiences and feedback from advocacy groups help guide our development programs. We are here for them.”
Alon Ben-Noon, CEO
NeuroSense in the Community
NeuroSense was established to help alleviate the challenges of patients. For that reason, we are dedicated to raising awareness of the diseases and assisting nonprofit organizations in their fundraising efforts.
NeuroSense in the Community
NeuroSense was established to help alleviate the challenges of patients. For that reason, we are dedicated to raising awareness of the diseases and assisting nonprofit organizations in their fundraising efforts.
Join Our Newsletter
